Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Patients With Major Depressive Disorder With an Inadequate Response to Current Antidepressant Treatment
NCT03093025 is registered in ClinicalTrials.gov with Taisho Pharmaceutical R&D Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Patients With Major Depressive Disorder With an Inadequate Response to Current Antidepressant Treatment
- Lead sponsor
- Taisho Pharmaceutical R&D Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 3, 2017
- Completion date
- December 4, 2018
- Enrollment
- 51 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.